Know Cancer

or
forgot password

Special Drug Use Investigation of Zevalin


N/A
N/A
N/A
Not Enrolling
Both
Non-Hodgkin's Lymphoma (NHL)

Thank you

Trial Information

Special Drug Use Investigation of Zevalin


Inclusion Criteria:



- Patients who received In-111 Zevalin to verify that expected biodistribution is
present.

Exclusion Criteria:

- Patients who are contraindicated based on the product label.

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Assessment of abnormal distribution of In-111 Zevalin by the investigator [Two scales; Yes or No]

Outcome Time Frame:

At 48-72 hours after In-111 Zevalin injection

Safety Issue:

No

Principal Investigator

Bayer Study Director

Investigator Role:

Study Director

Investigator Affiliation:

Bayer

Authority:

Japan: Ministry of Health, Labor and Welfare

Study ID:

15043

NCT ID:

NCT01479387

Start Date:

August 2008

Completion Date:

February 2011

Related Keywords:

  • Non-Hodgkin's Lymphoma (NHL)
  • Zevalin
  • CD20+
  • Non-Hodgkin's lymphoma
  • Mantle cell lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location